Bio-Rad to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, February 12, 2026

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a prominent player in the life science research and clinical diagnostics sectors, is set to unveil its financial results for the fourth quarter and full year 2025 on Thursday, February 12, 2026. The announcement will come after market close, followed by a conference call scheduled for 2:00 PM Pacific Time (5:00 PM Eastern Time) where management will discuss the outcomes.

Interested parties can join the call by dialing (800) 715-9871 within the U.S. or (646) 307-1963 internationally, using the access code 9562470. For those unable to participate live, a webcast of the conference call, along with a supplemental earnings presentation, will be accessible in the "Investor Relations" section on Bio-Rad's website under "Events & Presentations," at investors.bio-rad.com. A replay of the webcast will be available for up to a year following the event.

Based in Hercules, California, Bio-Rad is dedicated to the development, manufacturing, and marketing of diverse products that cater to the life sciences research and clinical diagnostics markets. With approximately 7,500 employees and reported revenues of $2.6 billion in 2024, the company serves a wide range of customers, including universities, hospitals, and biopharmaceutical companies. Bio-Rad’s commitment to innovation and quality aids in the advancement of science and contributes to saving lives.

Investors and analysts will be paying close attention to the upcoming financial results, as they may provide insights into the company’s performance, growth trajectory, and potential market challenges. For additional information, stakeholders can reach the investor relations team at 510-741-6104 or via email at ir@bio-rad.com.

As Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B) approaches the announcement of its fourth quarter and full year 2025 financial results slated for February 12, 2026, investors should prepare to carefully evaluate several key aspects that could influence stock performance.

Firstly, consider the broader trends in the life sciences and diagnostics markets. The increasing demand for innovative diagnostics solutions and advancements in biopharmaceutical research have positioned companies like Bio-Rad favorably. Investors should look for growth in revenue, particularly if management notes robust sales in key product segments such as research reagents and quality control products.

The company’s strong revenue of $2.6 billion in 2024 sets a solid foundation, but analysts will pay close attention to year-over-year growth rates. A continued upward trajectory could indicate strong market positioning and effective execution of their business strategy.

The impact of global economic conditions and supply chain constraints should also be assessed, particularly in reference to operating margins and overall profitability. Any comments from management regarding cost management strategies or pricing power will be pivotal.

The conference call following the earnings release will be essential for gauging management’s outlook on 2026. Look for insights regarding research and development investments, competitive advantages, and any strategic partnerships that could bolster Bio-Rad's market presence.

Furthermore, institutional investor sentiment would also be critical; examine any changes in insider trading dynamics leading up to the earnings report. Positive sentiment could indicate confidence in the company’s growth trajectory.

In summary, as Bio-Rad gears up for its earnings report, investors should focus on revenue growth, operational efficiency, and market positioning, keeping in mind the broader industry trends that could affect financial performance in 2026 and beyond.